To successfully develop a vaccine that is broadly protective against SARS, SARS-CoV-2, and related coronaviruses. After extensive animal safety and efficacy evaluations Vishwanath et al., Nature Biomedical Engineering 2023, this revolutionary digitally designed vaccine antigen underwent a "First-in-Human" Phase 1 clinical study. The trial was conducted at the NIHR Southampton and Cambridge Clinical Research Facilities and recruited healthy volunteers. The vaccine was injected into the skin via a needle-free device and results showed that it was safe and well tolerated.
Commenting on the significance of the trial results, Dr. Rebecca Kinsley, Chief Operating Officer of DIOSynVax, said: “While we are currently focused on developing influenza vaccines, this trial has demonstrated the nigeria telegram data robust safety profile of our Digital ImmunoOptimized Synthetic antigens and their ability to induce a broad immune response. This is a critical step forward in our journey towards developing hyper-seasonal influenza, pre-pandemic avian influenza, and ultimately a universal influenza vaccine.”
Professor Jonathan Heeney, Scientific Director of DIOSynVax, added: “The results of this clinical study using our technology provide a foundation for our influenza vaccine development. This technology offers several advantages including improved safety, fewer vaccinations required, and the ability to predict the emergence of new virus strains. We are excited to advance our mRNA-based influenza vaccine candidate and accelerate progress towards proof of concept in the coming months.